1. 1246PDTalimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (pts) with stage IIIB–IVM1c melanoma: Evidence for systemic effects in a phase II, single-arm study. (23rd October 2018) Authors: Gogas, H; Samoylenko, I; Schadendorf, D; Gutzmer, R; Grob, J J; Sacco, J J; Gorski, K; Anderson, A; Liu, C; Malvehy, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PO.6.127 Efavaleukin alfa, a novel IL-2 mutein, selectively expands regulatory t cells in patients with SLE: final results of a phase 1b multiple ascending dose study. (27th September 2022) Authors: Tchao, N; Sarkar, N; Hu, X; Zhang, R; Milmont, C; Shi Jin, Y; Chow, V; Kroenke, M; Gorski, K; Furie, R; Alan, K; Stanley, C Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A96 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗